NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage, biopharmaceutical company, today announced its Chairman of the Board and Chief Executive Officer, Prof Jonathan Javitt, MD, MPH, will be presenting updates to the Company’s business at the H.C. Wainwright BioConnect Virtual Conference.
NRx Pharmaceuticals (Nasdaq: NRXP) announced today that it has submitted an application for Emergency Use Authorization (EUA) to the US Food and Drug Administration (FDA) for the use of ZYESAMI® (aviptadil) in patients with Critical COVID-19 who are at immediate risk of death from Respiratory Failure despite treatment with approved therapy including Remdesivir and who are ineligible for enrollment into the ongoing ACTIV-3b NIH-sponsored trial.
NRx Pharmaceuticals (Nasdaq: NRXP) announced today that it has filed a provisional composition of matter patent application with the US Patent and Trademark Office entitled “Stable, Buffer-free Compositions of Vasoactive Intestinal Peptide (VIP).”
NRx Pharmaceuticals Files Breakthrough Therapy Designation Request for ZYESAMI® (aviptadil) in Patients at Immediate Risk of Death from COVID-19.
NRx Pharmaceuticals announced that Nasdaq has added the company to the Nasdaq Biotechnology Index (Nasdaq:NBI) effective December 20, 2021. The NBI is designed to measure the performance of a set of Nasdaq-listed biotechnology and pharmaceutical companies.
RADNOR, Pa., Nov. 16, 2021 (GLOBE NEWSWIRE) — NRx Pharmaceuticals (Nasdaq: NRXP) (NRx), a clinical-stage, biopharmaceutical company, today provided a business update and financial results for the quarter ended September 30, 2021. NRx will host a conference call Tuesday morning, November 16th, at 8:30 AM Eastern Time to discuss its business update and third-quarter financial […]
Conference Begins on November 15, 2021 RADNOR, Pa., Nov. 12, 2021 (GLOBE NEWSWIRE) — NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage, biopharmaceutical company, today announced its Chairman of the Board and Chief Executive Officer, Jonathan Javitt, will be presenting updates to the Company’s business at the H.C. Wainwright 7th Annual Israel Virtual Conference. Details of the presentation can […]
September 13, 2021 04:15 PM Eastern Daylight Time RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced a transformative collaboration with NRx Pharmaceuticals (NRx) (Nasdaq: NRXP). NRx is a company dedicated to creating innovative, life-saving treatments and bringing […]
RADNOR, Pa., Sept. 8, 2021 /PRNewswire/ — NRx Pharmaceuticals (NRx) (Nasdaq: NRXP) today announced that NRx’s management team will present and host one-on-one investor meetings at the upcoming H.C. Wainwright Global Investment Conference September 13-15, 2021. Conference: H.C. Wainwright 23rd Annual Global Investment Conference Format: Virtual on demand presentation and one-on-one meetings Presentation: Available on demand beginning September 13, […]